Technetium-99m

New Indication Approved for Verdye (Indocyanine Green for Injection, ICG) for Breast Sentinel Lymph Node Mapping

Retrieved on: 
Monday, February 5, 2024
Sentinel, Surgeon, Sentinel lymph node, ICG, USP, Survival, Breast cancer, Lymph, Injection, Patient, Technetium-99m, SLN, Physician, Radiation, Risk, Cancer, Hospital, Medical imaging

ATHLONE, Ireland, Feb. 5, 2024 /PRNewswire/ -- Diagnostic Green Plc (Diagnostic Green) is pleased to announce the approval of Verdye (ICG) for intraoperative identification of sentinel lymph nodes and visualisation pathways in breast cancer in Spain.

Key Points: 
  • ATHLONE, Ireland, Feb. 5, 2024 /PRNewswire/ -- Diagnostic Green Plc (Diagnostic Green) is pleased to announce the approval of Verdye (ICG) for intraoperative identification of sentinel lymph nodes and visualisation pathways in breast cancer in Spain.
  • The presence of lymphatic metastases is an important prognostic factor for the survival of breast cancer.
  • Sentinel lymph node biopsy (SLNB) continues to be a fundamental component of early breast cancer detection and is the current standard of care to help determine whether cancer has spread to the lymph nodes.
  • Verdye (Indocyanine Green, ICG) is available throughout EMEA and sold through a network of distributors or directly by Diagnostic Green.

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, June 7, 2023
Research, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Pharmaceutical, Science, Oncology, Therapy, Biopharmaceutical, Doctor of Philosophy, Marketing, Meilleur, Consultant, Clinical trial, G2G, PET, CRG, UCSD, Keystone, CMO, Biomarker, Associate, Sale, Rheumatoid arthritis, Translation, State Administrative Expenses, CCRA, Expense, FACEP, Political moderate, Medicine, Technetium-99m, Growth, NYSE, Pharmaceutical industry, Management, Patient

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces, in line with the Company’s Fix, Fund, Propel approach, details related to recently reported financial results for its first quarter ended March 31, 2023 and provides a business update.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announces, in line with the Company’s Fix, Fund, Propel approach, details related to recently reported financial results for its first quarter ended March 31, 2023 and provides a business update.
  • (Fix) In the first quarter of 2023, Selling, general and administrative expenses were down 36% compared to the same period in 2022.
  • Other income, net, was $946,000 during the first quarter of 2023 compared to other expense, net, of $8,000 during the same period in 2022.
  • During the first quarters of 2023 and 2022, we recognized interest expense of $263,000 and $4,000, respectively.

Navidea Biopharmaceuticals Files Appeal in CRG Case

Retrieved on: 
Thursday, December 1, 2022
Biotechnology, Health, Professional Services, Pharmaceutical, Legal, Judgement, NYSE American, History, Technetium-99m, Anonymous Online Speakers v. United States District Court for the District of Nevada, Macrophage, Biopharmaceutical, Therapy, Health, Annual report, Disease, District court, NYSE, Risk, Research, Equative case, Coronavirus, Appeal, Pharmaceutical industry

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No.
  • v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., with the 14th Court of Appeals of Texas for review by the appellate court.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
  • The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Clinical Trials, NYSE American, RA, History, Technetium-99m, Macrophage, Biopharmaceutical, Rheumatology, Health, Physician, Joint, Moderate, Drug Quality and Security Act, Annual report, Rheumatoid arthritis, Inflammation, Disease, NYSE, Risk, Research, Coronavirus, FDA, Pharmaceutical industry, Medical imaging, Patient

This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis (RA) patients switching to an anti-TNF therapy, addressing a large unmet medical need.

Key Points: 
  • This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis (RA) patients switching to an anti-TNF therapy, addressing a large unmet medical need.
  • These macrophage density changes may be observable weeks before disease modification can be detected with standard clinical assessments.
  • The NAV3-33 Phase 3 trial involves Tc99m tilmanocept imaging in participants with RA who are about to begin anti-TNF therapy.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Paclitaxel, Review, Coronavirus, Society, SEC, TAM, Risk, NYSE, Drug discovery, Immunotherapy, Biopharmaceutical, Securities Exchange Act of 1934, Securities Act of 1933, Tumor-associated macrophage, CD86, Disease, SITC, Forward-looking statement, Abstract, NYSE American, Neoplasm, Convention center, History, CD163, Technetium-99m, Boston Convention and Exhibition Center, Investigational New Drug, Health, Decision-making, Phenotype, Toxicity, CD80, Wound healing, Research, Annual report, Macrophage, Pharmaceutical industry, Cancer

The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.

Key Points: 
  • The results will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) to be held at the Boston Convention & Exhibition Center in person and virtually November 8-12, 2022 in Boston, MA.
  • These details were embargoed by SITC until the week of the meeting.
  • Abstract title and session information can be found on the SITC Annual Meeting website at: https://www.sitcancer.org/2022/home .
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Navidea Biopharmaceuticals to Host Third Quarter 2022 Earnings Conference Call and Business Update

Retrieved on: 
Friday, November 4, 2022
Biotechnology, Pharmaceutical, Health, Research, Risk, History, NYSE, NYSE American, Securities Exchange Act of 1934, Review, Health, Securities Act of 1933, Annual report, Coronavirus, Macrophage, Forward-looking statement, Decision-making, Disease, Technetium-99m, SEC, Pharmaceutical industry

In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navideas website.

Key Points: 
  • In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Navideas website.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
  • Navideas Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.
  • The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Securities Act of 1933, Disease, SEC, Macrophage, Review, NYSE, Annual report, Biopharmaceutical, Research, NYSE American, Technetium-99m, Immunotherapy, Coronavirus, History, Convention center, Boston Convention and Exhibition Center, Abstract, Society, Health, Securities Exchange Act of 1934, Decision-making, Forward-looking statement, Paclitaxel, Risk, Pharmaceutical industry, Book, Cancer

Further details of the abstract will be announced in a future press release once the meeting embargo is lifted.

Key Points: 
  • Further details of the abstract will be announced in a future press release once the meeting embargo is lifted.
  • Abstract title and session information can be found on the SITC Annual Meeting website at: https://www.sitcancer.org/2022/home .
  • Dr. Michael Rosol, Chief Medical Officer for Navidea, said, We are delighted by the opportunity to present these important preclinical results at this internationally recognized meeting.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Navidea Biopharmaceuticals Appoints Joshua Wilson to the Board of Directors; Announces Dates Related to its 2022 Annual Meeting of Stockholders

Retrieved on: 
Friday, September 30, 2022
Biotechnology, General Health, Health, Genetics, Pharmaceutical, People, Lynx, Corporation, Macrophage, Leadership, Biopharmaceutical, Research, Disease, National Western Stock Show, Audit, Club, Suite, Business administration, Securities Act of 1933, Annual general meeting, Company, NYSE American, Growth, History, Annual report, Nousukausi, Rolling Hills, Attention, SEC, Executive, NYSE, Securities Exchange Act of 1934, Senior, Health, Review, Partnership, Forward-looking statement, Technetium-99m, Bank, Coronavirus, Board of directors, Board, Regis University, Risk, State, Biotechnology, Decision-making, Webcast, Security (finance), Management, Financial adviser, Shareholder, By-law

Mr. Wilson currently serves on the board of directors of Lynx Energy ULC, with prior board experience with First Western Trust.

Key Points: 
  • Mr. Wilson currently serves on the board of directors of Lynx Energy ULC, with prior board experience with First Western Trust.
  • Navidea Board Chair Alexander L. Cappello said, I am proud to welcome Josh to the Navidea Board of Directors.
  • Navidea also announced that its 2022 Annual Meeting of Stockholders (2022 Annual Meeting) will be held on Thursday, December 8, 2022 at 1:00 pm Eastern Standard Time.
  • Any proposal or nomination received outside of such dates will be considered untimely and will not be considered at the 2022 Annual Meeting.

Navidea Biopharmaceuticals Announces Presentation of Results from its Two Phase 2B Clinical Trials in Rheumatoid Arthritis at Upcoming American College of Rheumatology Annual Meeting

Retrieved on: 
Thursday, September 15, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Securities Exchange Act of 1934, NYSE, Securities Act of 1933, Conditional sentence, NYSE American, Health, Macrophage, Review, Forward-looking statement, Patient, Technetium-99m, Risk, History, Annual report, Coronavirus, Research, SEC, Decision-making, Disease, Pharmaceutical industry

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Key Points: 
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
  • Navideas Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.
  • The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.
  • You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be incorrect.

Navidea Biopharmaceuticals Announces Opening of Nine New Sites in its Pivotal Phase 3 Trial in Rheumatoid Arthritis and Termination of Binding Memorandum of Understanding with Jubilant Radiopharma

Retrieved on: 
Thursday, September 1, 2022
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Technetium-99m, Rheumatoid arthritis, Securities Exchange Act of 1934, NYSE, Securities Act of 1933, Research, Macrophage, Distribution, Technetium (99mTc) tilmanocept, Disease, Decision-making, Coronavirus, NYSE American, MOU, Drug Quality and Security Act, Risk, Food, Physician, SEC, Memorandum, Biopharmaceutical, Joint, Health, Company, History, Technetium, Rheumatology, Annual report, Review, Forward-looking statement, Moderate, Pharmaceutical industry, Patient

A total of 12 sites open for the NAV3-33 study will enable faster patient enrollment and data gathering.

Key Points: 
  • A total of 12 sites open for the NAV3-33 study will enable faster patient enrollment and data gathering.
  • The Company also announced the termination of the Memorandum of Understanding (MOU) with Jubilant Radiopharma, originally signed on August 9, 2020.
  • In connection with the MOU, Jubilant Radiopharma also made a $1 million equity investment in exchange for a limited exclusivity period.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.